Trial Profile
To investigate the efficacy and safety of bortezomib as maintenance therapy for untreated multiple myeloma patients ineligible for autologous stem cell transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 May 2012 New trial record